This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Absorption Systems Registers With FDA As A Generic Drug Facility Under GDUFA

EXTON, Pa., March 25, 2013 /PRNewswire/ -- The preclinical contract research organization Absorption Systems, a global leader in pharmacokinetic testing of drugs and the world leader in the in-vitro classification of drugs according to the Biopharmaceutics Classification System (BCS), announces that it has registered with the United States Food and Drug Administration (FDA) as a generic drug facility under the Generic Drug User Fee Amendments of 2012 (GDUFA). As required by GDUFA, the company self-identified as a BCS, bioequivalence (BE), and bioavailability (BA) testing facility and is now on the FDA's list of registered facilities. In addition, to take advantage of the emerging markets of Central and South America, Absorption Systems' Panama operation will be registered with the FDA as a generic drug facility under GDUFA in the second half of 2013. Central and South America will benefit tremendously from the regional presence of an established leader in the field of BCS, BE and BA.  

GDUFA, which applies to generic drugs, is part of the 2012 renewal of the Prescription Drug User Fee Act (PDUFA), originally enacted in 1992 and renewed every five years thereafter. Both authorize the FDA to collect user fees from drug sponsors at the time of submission of a marketing application: new drug application (NDA) for a proprietary, branded drug or abbreviated new drug application (ANDA) for a generic drug. In exchange, a time limit is imposed on the agency's review of each application. PDUFA is credited with greatly improving the efficiency of new drug reviews by the FDA; the average review time for priority drugs has dropped from 24 months in 1992 (pre-PDUFA) to 13 months in 2012. GDUFA is expected to help reduce the current backlog of generic drug reviews, which is due to the increase in the number of generic drug applications, their growing complexity, and the need to inspect the growing number of generic drug facilities located overseas.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs